Edwards Lifesciences (NYSE:EW) said today that it received FDA approval for Triformis Resilia, its surgical tricuspid valve replacement.
The daily pills nearly doubled survival time, with fewer severe side effects, in a study that randomly assigned the experimental drug or more chemotherapy to 500 patients whose metastatic, or spreading, cancer had quit responding to prior treatment.
Researchers at Lund University have developed a blood test capable of detecting signs of breast cancer recurrence long before recurrence becomes visible on imaging or causes symptoms.
Researchers have solved a long-standing mystery about why physical forces slow cancer growth—and the answer could reshape how the disease is treated. A multidisciplinary team from University of Galway, CÚRAM, the Taighde Éireann-Research Ireland Centre for Medical Devices, and KU Leuven in Belgium built an innovative AI accelerated computational model to test the theory.
Researchers at Washington University School of Medicine in St. Louis have developed an AI-based classifier that distinguishes between four common brain diseases that cause dementia: Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and dementia with Lewy bodies, as well as healthy brain aging.
Gene editing may help people born with dangerously high cholesterol lower their levels with just one infusion.
How the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.
Coredio’s AI software is used to monitor HF parameters via wearables and standard blood pressure cuffs.
MannKind (Nasdaq:MNKD) announced today that it received FDA approval for its Afrezza inhaled insulin powder for children.
A new brain imaging test can detect a key hallmark of Alzheimer’s disease before symptoms appear and earlier than the method currently used in clinical practice in the United States and Europe, report University of Pittsburgh School of Medicine researchers in The Lancet.